Inactive Instrument

Press Releases Cellectar Biosciences Inc Nasdaq

Equities

US15117F2039

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-14	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	05-14	AQ
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	05-08	AQ
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	05-07	AQ
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	03-27	AQ
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	03-20	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	03-18	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	03-14	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	03-04	AQ
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-07	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	01-30	AQ
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	01-25	AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	01-23	AQ
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	01-22	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	01-17	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data	01-16	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	01-15	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	01-12	AQ
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	01-11	AQ
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia	01-08	AQ
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024	01-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectar Biosciences Inc Nasdaq

Equities

US15117F2039

Press Releases

Filters